指南与共识妇科肿瘤

ASCO指南:PARP抑制剂在卵巢癌管理中的应用

PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline.
指南 / 共识 · J Clin Oncol · 2020-08-13

该指南由ASCO制定,基于2011至2020年发表的随机对照和开放标签试验,为上皮性卵巢癌、输卵管癌或原发性腹膜癌患者提供PARP抑制剂使用推荐。指南针对未接受过PARP抑制剂的患者,涉及一线维持治疗、复发治疗及不良反应管理,并指出PARP抑制剂在复发设置中不与化疗、其他靶向药物或免疫肿瘤药物联合使用(临床试验除外)。

要点

  • 新诊断III-IV期高级别浆液性或子宫内膜样卵巢癌对一线铂类化疗完全或部分缓解者,推荐尼拉帕利维持治疗。
  • 存在胚系或体细胞BRCA1/2致病或可能致病突变的患者应接受奥拉帕利治疗。
  • 复发卵巢癌铂类治疗后6个月内未复发且未用过PARP抑制剂者,若BRCA突变或基因组不稳定,可接受PARP抑制剂治疗。

核心结论

  • PARP抑制剂可用于特定上皮性卵巢癌患者的一线维持、二线及以上维持及复发治疗,但需根据BRCA状态和基因组不稳定性选择。

研究设计与样本

  • 制定机构:ASCO;方法:系统文献检索2011至2020年发表的随机对照和开放标签试验,基于证据、FDA批准和共识形成推荐。

主要发现

  • 系统综述识别了17项符合条件的试验。

关键数值与推荐

  • 新诊断III-IV期高级别浆液性或子宫内膜样卵巢癌对一线铂类化疗完全或部分缓解者,应提供尼拉帕利维持治疗。
  • 胚系或体细胞BRCA1/2致病或可能致病突变者应接受奥拉帕利治疗。
  • III-IV期卵巢癌伴g/sBRCA1/2和/或基因组不稳定且对化疗联合贝伐珠单抗部分或完全缓解者,可提供奥拉帕利联合贝伐珠单抗。
  • 未接受过PARP抑制剂且对铂类治疗有反应的复发卵巢癌患者(无论BRCA状态),可提供单药PARP抑制剂维持治疗(二线或以上)。
  • 复发卵巢癌铂类治疗后6个月内未复发、未接受过PARP抑制剂且伴g/sBRCA1/2或肿瘤基因组不稳定者,应提供PARP抑制剂治疗。

临床怎么用

  • 临床应根据BRCA突变状态和基因组不稳定性,为符合条件的卵巢癌患者选择PARP抑制剂维持或治疗,并管理特定不良事件。

局限性

  • 需要数据支持PARP抑制剂在任何设置中的再次使用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To provide recommendations on the use of poly(ADP-ribose) polymerase inhibitors (PARPis) for management of epithelial ovarian, tubal, or primary peritoneal cancer (EOC). METHODS: Randomized, controlled, and open-labeled trials published from 2011 through 2020 were identified in a literature search. Guideline recommendations were based on the review of the evidence, US Food and Drug Administration approvals, and consensus when evidence was lacking. RESULTS: The systematic review identified 17 eligible trials. RECOMMENDATIONS: The guideline pertains to patients who are PARPi naïve. All patients with newly diagnosed, stage III-IV EOC whose disease is in complete or partial response to first-line, platinum-based chemotherapy with high-grade serous or endometrioid EOC should be offered PARPi maintenance therapy with niraparib. For patients with germline or somatic pathogenic or likely pathogenic variants in BRCA1 (g/sBRCA1) or BRCA2 (g/sBRCA2) genes should be treated with olaparib. The addition of olaparib to bevacizumab may be offered to patients with stage III-IV EOC with g/sBRCA1/2 and/or genomic instability and a partial or complete response to chemotherapy plus bevacizumab combination. Maintenance therapy (second line or more) with single-agent PARPi may be offered for patients with EOC who have not received a PARPi and have responded to platinum-based therapy regardless of BRCA mutation status. Treatment with a PARPi should be offered to patients with recurrent EOC that has not recurred within 6 months of platinum-based therapy, who have not received a PARPi and have a g/sBRCA1/2, or whose tumor demonstrates genomic instability. PARPis are not recommended for use in combination with chemotherapy, other targeted agents, or immune-oncology agents in the recurrent setting outside the context of a clinical trial. Recommendations for managing specific adverse events are presented. Data to support reuse of PARPis in any setting are needed.Additional information is available at www.asco.org/gynecologic-cancer-guidelines.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Tew WP, Lacchetti C, Ellis A, et al. PARP Inhibitors in the Management of Ovarian Cancer: ASCO Guideline. J Clin Oncol. 2020. PMID: 32790492. doi:10.1200/JCO.20.01924

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。